8-K
BIOTRICITY INC. (BTCY)
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
WASHINGTON,DC 20549
FORM8-K
CURRENTREPORT PURSUANT
TOSECTION 13 OR 15(D) OF THE
SECURITIESEXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 8, 2021
BIOTRICITYINC.
(Exact name of registrant as specified in its charter)
| Nevada | 000-56074 | 47-2548273 |
|---|---|---|
| (State<br> or Other Jurisdiction of<br><br> Incorporation or Organization) | (Commission<br><br> File Number) | (IRS<br> Employer<br><br> Identification No.) |
275Shoreline Drive, Suite 150Redwood City, California 94065
(Address of Principal Executive Offices)
**(650)832-1626(**Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| [ ] | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Securities<br> registered pursuant to Section 12(b) of the Act: note | |
| [ ] | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Securities<br> registered pursuant to Section 12(b): None | |
| Indicate<br> by check mark whether the registrant is an emerging growth company as defined in Rule<br> 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the<br> Securities Exchange Act of 1934 (§240.12b-2 of this chapter).<br><br> <br><br><br> <br>Emerging<br> growth company [X] | |
| If<br> an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period<br> for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<br> [X] |
Item2.02 Results of Operations and Financial Condition.
On February 11, 2021, Biotricity Inc. (the “Company”) issued a press release reporting its financial results for the period ended December 31, 2020. The press release is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 8.01. Other Events
On February 8, 2021, the Company issued a press release announcing that it would be reporting its financial results for the quarter ended December 31, 2020. A copy of the press release is attached hereto as exhibit 99.2.
Item9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description |
|---|---|
| 99.1 | Press release |
| 99.2 | Biotricity to Report Third Quarter Fiscal 2021 Financial Results on February 11, 2021 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: February 12, 2021
| BIOTRICITY<br> INC. | |
|---|---|
| By: | /s/ John Ayanoglou |
| John<br> Ayanoglou<br><br> <br>Chief<br> Financial Officer |
Exhibit 99.1
BiotricityReports Record Revenue; Tops $1.0 Million in Quarterly Revenue for the First Time
Thu, February 11, 2021, 4:05 PM·6 min read
**REDWOODCITY, CA / ACCESSWIRE / February 11, 2021 /**Biotricity, Inc. (OTCQB:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, is pleased to provide unaudited, preliminary financial results for its fiscal 2021 third quarter, which ended December 31, 2020. Full financial results will be posted on EDGAR on February 16, 2021. Biotricity’s Q3 results continued a trend of both sequential and year over year revenue growth, with revenue setting a new quarterly record in the fiscal third quarter.
For fiscal Q3 2021, management is reporting the following highlights:
| ● | Revenue<br> of $1 million (USD) - a milestone for Company in its quarterly results |
|---|---|
| ● | Year-over-year<br> quarterly revenue increased 162% |
| ● | Sequential<br> quarter-over-quarter revenue increase 34.5% |
“We achieved significant growth during a period of restricted travel due to Covid, so we are even more optimistic about our growth potential as the business environment unlocks,” stated Waqaas Al-Siddiq, CEO of Biotricity. “Our sequential quarterly growth really illustrates the importance of our technology and model, where we are enabling a cardiologist while improving patient care. Monthly sequential growth is a sure sign that our platform is on target, and we are on track to continue our strong sequential and year over year growth.”
“During the three months ended December 31, 2020, the Company experienced a gross margin of 49.2% compared to 43.6% in the preceding quarter,” said Biotricity’s CFO, John Ayanoglou. “This improvement is consistent with our prior forecast that the cost of devices sold and other technology associated fees will become a lower percentage of revenues as sales volumes expand. We had significant product development activity during the quarter, including an FDA filing, so our net loss of $0.11 per share was higher than the net loss of $0.085 cents per share in Q2.”
In the current quarter (fiscal Q4 2021) and for the remainder of calendar 2021, the Company is guiding to continued triple-digit revenue growth on a year over year basis. With added resources from a convertible debt financing completed in January 2021, Biotricity is currently interviewing additional sales personnel as part of a planned geographic expansion into additional states. The Company filed a 510(K) seeking FDA approval for its new Biotres Holter product on December 31, 2020 and expects the review process to run approximately four months.
Dr. Waqaas Al-Siddiq added, “We are coming out of the gate at a full sprint in 2021, with salesforce expansion and work underway on new products that will enable us to target a much larger segment of the cardiologist patient population. We spent years developing best-in-class technology coupled with a compelling technology as a service model. We are pleased with our results and look forward to further progress in upcoming quarters.”
ConferenceCall Information
Biotricity management will host a conference call and live webcast for analysts and investors on February 11, 2021 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss the company’s financial results.
To access the live call, dial 323-289-6581 (local) or 866-248-8441 (toll-free) and give the participant passcode 9555546.
A live webcast of the conference call can be accessed by clicking on the following link: Webcast. Audio will stream through your selected device. A full replay of the presentation will be available at the same link shortly after the conclusion of the live presentation.
The live and archived webcast of the conference call will also be accessible on the Investor Relations section of the company’s website at www.biotricity.com. The phone replay will be available approximately two hours following the end of the call and will remain available for one week. To access the call replay dial-in information, please use the following link: Click Here
AboutBiotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic products for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
ImportantCautions Regarding Forward-Looking Statements
Anystatements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-lookingstatements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiableby use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,”“expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,”“project,” or “goal” or the negative of these words or other variations on these words or comparable terminology.Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives, and goals of managementfor future operations, including plans, objectives, or goals relating to the design, development, and commercialization of Biofluxor any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings(including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’sfuture financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptionsunderlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements arenot meant to predict or guarantee actual results, performance, events, or circumstances and may not be realized because they arebased upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates, and assumptions and aresubject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual resultsand the timing of certain events and circumstances may differ materially from those described by the forward-looking statementsas a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-lookingstatements or cause actual results to differ materially from expected or desired results may include, without limitation, theCompany’s inability to obtain additional financing, the significant length of time and resources associated with the developmentof its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’sbusiness, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existingor increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failureto implement the Company’s business plans or strategies. These and other factors are identified and described in more detailin the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in orderto reflect any event or circumstance that may arise after the date of this release.
Contacts:
Investor Relations:
Biotricity Inc.
1-800-590-4155
investors@biotricity.com
Todd Kehrli or Mark Forney
MKR Investor Relations, Inc.
btcy@mkr-group.com
**SOURCE:**Biotricity, Inc.
View source version on accesswire.com:
https://www.accesswire.com/629262/Biotricity-Reports-Record-Revenue-Tops-10-Million-in-Quarterly-Revenue-for-the-First-Time
Exhibit99.2
Biotricityto Report Third Quarter Fiscal 2021 Financial Results on February 11, 2021
Biotricity
Mon, February 8, 2021, 8:00 AM·4 min read
REDWOOD CITY, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will discuss the highlights of its financial results for the third quarter of fiscal 2021, ended December 31, 2020, on Thursday, February 11, 2021, after the close of the market. Full financial results will be filed and available on Tuesday February 16, 2021.
Biotricity management will host a conference call and live webcast for analysts and investors on February 11, 2021 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss the company's financial results.
To access the live call, dial 323-289-6581 (local) or 866-248-8441 (toll free) and give the participant passcode 9555546.
A live webcast of the conference call can be accessed by clicking on the following link: Webcast. Audio will stream through your selected device. A full replay of the presentation will be available at the same link shortly after the conclusion of the live presentation.
The live and archived webcast of the conference call will also be accessible on the Investor Relations section of the company’s website at www.biotricity.com. The phone replay will be available approximately two hours following the end of the call, and will remain available for one week. To access the call replay dial-in information, please use the following link: Click Here
AboutBiotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic products for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts:
Investor Relations:
Biotricity Inc.
1-800-590-4155
investors@biotricity.com
Todd Kehrli or Mark Forney
MKR Investor Relations, Inc.
btcy@mkr-group.com